Ascend West and Central Africa could play an important role in mitigating the impact of COVID-19 in Africa, according to an opinion piece by David Molyneux, emeritus professor and former director of the Liverpool School of Tropical Medicine (LSTM).Read the opinion piece
The new UK aid programme is managed by four leading development organisations. Together we will deliver more than 400 million treatments to help several countries to reach the elimination threshold for diseases and promote long-term sustainable change.
We will work alongside ministries of health, communities and partners including the World Health Organization (WHO) in endemic countries to deliver one of the most significant NTD programmes in history.
Ascend also gives Sightsavers the opportunity to continue the momentum, of several other NTD programmes that finished in 2019, including:
The video below shows the work already achieved to tackle lymphatic filariasis in the Bijagos Islands in Guinea-Bissau. The Ascend programme will build on this work, and that of many other programmes, to help us treat these devastating diseases.
To achieve Ascend’s goals, Sightsavers is working with partners including Mott Macdonald, the Schistosomiasis Control Initiative and the Liverpool School of Tropical Medicine, as well as DFID.
The Ascend consortium is made up of four of DFID’s established partners, responsible for NTD programming in collaboration with national governments. Ascend will build on this by working with partners and small/medium enterprises to fight the diseases and eliminate them wherever possible.
Every person has a part to play in eliminating these diseases. Together we can enhance the health, quality of life and future wellbeing of people affected by these painful, poverty-trapping conditions.
Sightsavers is working with partners and ministries of health in 13 countries:
Lokoto Samengoy has worked as a nurse in DRC for 12 years, helping patients with lymphatic filariasis. The disease causes their limbs to swell painfully, but can be managed through daily care. “When we treat patients, we also explain what the problem is with their legs,” she says.
Lokoto’s work is funded by DFID and can now continue thanks to the Ascend programme.